0
0.5
1
1.5
2+
Ventilation
77%
Improvement
Relative Risk
ICU admission
92%
Progression
68%
primary
Hospitalization time
29%
Casirivimab/i.. Komagamine et al. EARLY TREATMENT
Is early treatment with casirivimab/imdevimab beneficial for COVID-19?
Retrospective 128 patients in Japan
Lower ICU admission (p=0.041) and progression (p=0.006)
c19early.org
Komagamine et al., J. General and Fami.., Dec 2021
Favors casirivimab/im..
Favors control